NCT01828112 2025-02-07LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and CrizotinibNovartisPhase 3 Completed231 enrolled 33 charts
NCT01828099 2025-01-16LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung CancerNovartisPhase 3 Completed376 enrolled 34 charts 1 FDA
NCT03546894 2024-07-15A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) InhibitorsTakedaCompleted111 enrolled
NCT02299505 2022-02-09Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)NovartisPhase 1 Completed306 enrolled
NCT02450903 2021-03-30LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.NovartisPhase 2 Completed20 enrolled 12 charts
NCT01772797 2020-12-19Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung CancerNovartisPhase 1 Completed22 enrolled
NCT02292550 2020-12-17Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.NovartisPhase 1 Completed27 enrolled
NCT01685138 2019-03-26LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung CancerNovartisPhase 2 Completed124 enrolled 18 charts
NCT01283516 2019-03-15A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma KinaseNovartisPhase 1 Completed304 enrolled 37 charts
NCT02040870 2019-02-20LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With CrizotinibNovartisPhase 1/2 Completed103 enrolled 23 charts
NCT01685060 2017-06-19LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and CrizotinibNovartisPhase 2 Completed140 enrolled 17 charts